Charles Schwab Investment Management Inc Fate Therapeutics Inc Transaction History

Charles Schwab Investment Management Inc

  • $519 Billion
  • Q2 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 879,375 shares of FATE stock, worth $3.14 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
879,375
Previous 956,331 8.05%
Holding current value
$3.14 Million
Previous $7.02 Million 58.91%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024
SELL
$3.26 - $7.08 $250,876 - $544,848
-76,956 Reduced 8.05%
879,375 $2.88 Million
Q1 2024

May 08, 2024
SELL
$3.54 - $8.35 $94,475 - $222,844
-26,688 Reduced 2.71%
956,331 $7.02 Million
Q4 2023

Feb 06, 2024
BUY
$1.65 - $3.94 $158,901 - $379,437
96,304 Added 10.86%
983,019 $3.68 Million
Q3 2023

Nov 08, 2023
BUY
$2.02 - $5.04 $504,862 - $1.26 Million
249,932 Added 39.25%
886,715 $1.88 Million
Q2 2023

Aug 09, 2023
BUY
$4.76 - $6.59 $85,432 - $118,277
17,948 Added 2.9%
636,783 $3.03 Million
Q1 2023

May 11, 2023
BUY
$4.24 - $11.12 $17,816 - $46,726
4,202 Added 0.68%
618,835 $3.53 Million
Q4 2022

Feb 13, 2023
BUY
$9.86 - $23.83 $129,708 - $313,483
13,155 Added 2.19%
614,633 $6.2 Million
Q3 2022

Nov 14, 2022
SELL
$21.04 - $36.06 $4.64 Million - $7.95 Million
-220,505 Reduced 26.83%
601,478 $13.5 Million
Q2 2022

Aug 15, 2022
BUY
$17.78 - $42.39 $117,365 - $279,816
6,601 Added 0.81%
821,983 $20.4 Million
Q1 2022

May 13, 2022
BUY
$29.67 - $60.28 $613,397 - $1.25 Million
20,674 Added 2.6%
815,382 $31.6 Million
Q4 2021

Feb 11, 2022
BUY
$47.84 - $64.34 $831,507 - $1.12 Million
17,381 Added 2.24%
794,708 $46.5 Million
Q3 2021

Nov 16, 2021
BUY
$59.27 - $95.73 $11.5 Million - $18.6 Million
194,189 Added 33.3%
777,327 $46.1 Million
Q2 2021

Aug 16, 2021
BUY
$67.25 - $92.52 $1.26 Million - $1.74 Million
18,796 Added 3.33%
583,138 $50.6 Million
Q1 2021

May 17, 2021
BUY
$72.16 - $117.4 $6.06 Million - $9.85 Million
83,914 Added 17.47%
564,342 $46.5 Million
Q4 2020

Feb 16, 2021
BUY
$38.09 - $100.95 $241,528 - $640,123
6,341 Added 1.34%
480,428 $43.7 Million
Q3 2020

Nov 13, 2020
BUY
$30.41 - $40.5 $906,674 - $1.21 Million
29,815 Added 6.71%
474,087 $19 Million
Q2 2020

Aug 14, 2020
BUY
$20.21 - $35.23 $1.19 Million - $2.07 Million
58,866 Added 15.27%
444,272 $15.2 Million
Q1 2020

May 15, 2020
BUY
$17.28 - $31.88 $89,752 - $165,584
5,194 Added 1.37%
385,406 $8.56 Million
Q4 2019

Feb 07, 2020
BUY
$13.39 - $20.73 $519,572 - $804,386
38,803 Added 11.37%
380,212 $7.44 Million
Q3 2019

Nov 08, 2019
BUY
$15.47 - $22.5 $3.26 Million - $4.74 Million
210,836 Added 161.47%
341,409 $5.3 Million
Q2 2019

Aug 09, 2019
SELL
$15.61 - $20.44 $214,777 - $281,233
-13,759 Reduced 9.53%
130,573 $2.65 Million
Q1 2019

May 14, 2019
BUY
$13.15 - $18.71 $76,191 - $108,405
5,794 Added 4.18%
144,332 $2.54 Million
Q4 2018

Feb 14, 2019
BUY
$11.48 - $16.98 $316,595 - $468,274
27,578 Added 24.85%
138,538 $1.78 Million
Q3 2018

Nov 13, 2018
BUY
$8.75 - $16.29 $49,525 - $92,201
5,660 Added 5.38%
110,960 $1.81 Million
Q2 2018

Aug 08, 2018
BUY
$9.16 - $13.48 $71,448 - $105,144
7,800 Added 8.0%
105,300 $1.2 Million
Q1 2018

May 07, 2018
BUY
$6.3 - $13.77 $198,450 - $433,755
31,500 Added 47.73%
97,500 $952,000
Q3 2017

Nov 13, 2017
BUY
$2.6 - $4.31 $171,600 - $284,460
66,000
66,000 $262,000

Others Institutions Holding FATE

# of Institutions
190
Shares Held
123M
Call Options Held
15K
Put Options Held
14K
View Full List

About FATE THERAPEUTICS INC

FATE Quotes by TradingView
  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $346M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email